The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) ≥10: a decision centered on empowering patients and their physicians

Vivek Subbiah; David B. Solit; Timothy A. Chan; Razelle Kurzrock

doi:10.1016/j.annonc.2020.07.002

The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) ≥10: a decision centered on empowering patients and their physicians

Authors: Vivek Subbiah, David B. Solit, Timothy A. Chan, Razelle Kurzrock - Annals of Oncology 2020 cited by 250

The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) ≥10: a decision centered on empowering patients and their physicians | Litlas